|
US3254124A
(en)
|
1962-06-29 |
1966-05-31 |
Parke Davis & Co |
Aminoketones and methods for their production
|
|
CH535201A
(en)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Process for the resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone into the optically active isomers
|
|
US4670459A
(en)
|
1984-10-03 |
1987-06-02 |
Merrell Dow Pharmaceuticals Inc. |
Method of alleviating withdrawal symptoms
|
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
|
DE19619665C2
(en)
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemate separation of ketamine
|
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
|
US6382204B1
(en)
|
1999-10-14 |
2002-05-07 |
Becton Dickinson And Company |
Drug delivery system including holder and drug container
|
|
US6962151B1
(en)
|
1999-11-05 |
2005-11-08 |
Pari GmbH Spezialisten für effektive Inhalation |
Inhalation nebulizer
|
|
SI1257648T2
(en)
|
2000-02-23 |
2016-11-30 |
Amgen Inc. |
Antagonistic selective binding agents of osteoprotegerin binding protein
|
|
BRPI0002693B8
(en)
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
process for obtaining the enantiomers of ketamine and its pharmaceutically acceptable salts
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
JP2006510618A
(en)
|
2002-11-18 |
2006-03-30 |
ヤウポン セラピューティクス，インコーポレーテッド |
Analgesic use of norketamine and ketamine / norketamine prodrugs
|
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
US7928132B2
(en)
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
|
KR101271263B1
(en)
|
2005-09-28 |
2013-06-07 |
아우리스 메디칼 아게 |
Pharmaceutical compositions for the treatment of inner ear disorders
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
BRPI0809843A2
(en)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND"
|
|
US20120225949A1
(en)
*
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US20110038807A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
EP2830604A4
(en)
|
2012-03-30 |
2015-08-19 |
Gen Hospital Corp |
COMPOSITIONS COMPRISING SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSION
|
|
KR20150096370A
(en)
|
2012-08-23 |
2015-08-24 |
스튜어트 엘. 웨그 |
Anxiolytic composition, formulation and method of use
|
|
US20140274981A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
DK2968221T3
(en)
|
2013-03-15 |
2019-08-05 |
Janssen Pharmaceutica Nv |
PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
|
|
DK2983787T3
(en)
|
2013-04-12 |
2020-01-06 |
Icahn School Med Mount Sinai |
Procedure for the treatment of post-traumatic stress disorder
|
|
HUE056378T2
(en)
*
|
2013-09-13 |
2022-02-28 |
Univ Chiba Nat Univ Corp |
Application of r-ketamine and salt thereof as pharmaceuticals
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
EP3094312B1
(en)
|
2014-01-14 |
2019-03-13 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
JP6462002B2
(en)
|
2014-04-29 |
2019-01-30 |
ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション |
Novel compounds having therapeutic effects on immune diseases and uses thereof
|
|
KR20170040800A
(en)
|
2014-08-13 |
2017-04-13 |
얀센 파마슈티카 엔.브이. |
Method for the treatment of depression
|
|
AU2015318123A1
(en)
|
2014-09-15 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
DK3215147T3
(en)
|
2014-11-04 |
2024-04-02 |
Acadia Pharm Inc |
NEUROTENANT NORKETAMINE COMPOUNDS AND METHODS
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US11426366B2
(en)
|
2015-05-15 |
2022-08-30 |
Arizona Board Of Regents On Behalf Of The Universsity Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20200297734A1
(en)
|
2015-06-19 |
2020-09-24 |
Melt Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for anesthesiological applications
|
|
US9918993B2
(en)
|
2015-06-19 |
2018-03-20 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for anesthesiological applications
|
|
CN107847469A
(en)
|
2015-06-27 |
2018-03-27 |
美国神农制药责任有限公司 |
Ketamine transdermal delivery system
|
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
CA3019012A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US20200261442A1
(en)
|
2016-08-26 |
2020-08-20 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
US11103499B2
(en)
|
2016-08-26 |
2021-08-31 |
EXCIVA (UG) (haftungsbeschränkt) |
Compositions and methods thereof
|
|
WO2018075481A1
(en)
|
2016-10-17 |
2018-04-26 |
Yale University |
Compounds, compositions and methods for treating or preventing depression and other diseases
|
|
AU2017351437B2
(en)
|
2016-10-27 |
2022-01-27 |
National University Corporation Chiba University |
Application of (S)-norketamine and salt thereof as pharmaceutical
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
EP3562529A4
(en)
|
2016-12-27 |
2021-03-03 |
Action Medical Technologies, LLC |
Apparatuses and method for injecting medicaments
|
|
AU2018215056A1
(en)
|
2017-01-31 |
2019-08-08 |
Charles E. Inturrisi |
D-methadone and its derivatives for use in the treatment of disorders of the nervous system
|
|
US11478467B2
(en)
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
CA3064846A1
(en)
|
2017-05-25 |
2018-11-29 |
Glytech, Llc |
Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
Hydroxynorketamine for the use in the treatment of depression
|
|
US20200405663A1
(en)
|
2017-09-27 |
2020-12-31 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
|
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
US10869838B2
(en)
|
2017-10-10 |
2020-12-22 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
CN107823195A
(en)
|
2017-11-24 |
2018-03-23 |
无锡市精神卫生中心 |
Application of the R ketamines in depression acute stages treated
|
|
EP3505509A1
(en)
|
2017-12-29 |
2019-07-03 |
Université de Liège |
Methods for the preparation of arylcycloalkylamine derivatives
|
|
PL3737665T3
(en)
|
2018-01-10 |
2026-04-20 |
XWPharma Ltd. |
Prodrugs of ketamine, compositions and uses thereof
|
|
US11980595B2
(en)
|
2018-02-15 |
2024-05-14 |
National University Corporation Chiba University |
Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
|
|
WO2019169165A1
(en)
|
2018-02-28 |
2019-09-06 |
Novocine Therapeutics, Llc |
Ketamine and ketamine-related compounds for the treatment of neurological disorders
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES
|
|
WO2019213551A1
(en)
|
2018-05-04 |
2019-11-07 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
BR112020023882A2
(en)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
method to treat major depressive disorder
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
CN112702995A
(en)
|
2018-10-05 |
2021-04-23 |
克雷西奥生物科技有限公司 |
Treatment regimen of esketamine for treatment of major depression
|
|
EP3863617A1
(en)
|
2018-10-11 |
2021-08-18 |
Clexio Biosciences Ltd. |
Esketamine for use in treating major depressive disorder
|
|
WO2020138491A1
(en)
|
2018-12-27 |
2020-07-02 |
国立大学法人千葉大学 |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
|
|
PL3908570T3
(en)
|
2019-01-11 |
2024-07-01 |
Alar Pharmaceuticals Inc. |
Ketamine pamoate and use thereof
|
|
WO2020198039A1
(en)
|
2019-03-23 |
2020-10-01 |
Sermone Sandra |
Ketamine for treatment of sensory processing deficits
|
|
EP3956300A1
(en)
|
2019-04-16 |
2022-02-23 |
Janssen Pharmaceutica NV |
Synthetic methods of preparing esketamine
|
|
EP3968979A4
(en)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
US11007200B2
(en)
|
2019-08-21 |
2021-05-18 |
MediSynergics, LLC |
Cycloalkyl-diamines for the treatment of pain
|
|
PH12022550775A1
(en)
|
2019-12-20 |
2023-08-23 |
Alar Pharmaceuticals Inc |
Long-acting injectable formulations of ketamine pamoate salts
|
|
CN119241381A
(en)
|
2019-12-26 |
2025-01-03 |
吉尔伽美什制药公司 |
Arylcyclohexylamine derivatives and their use in the treatment of mental disorders
|
|
EP4084786A1
(en)
|
2019-12-30 |
2022-11-09 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
JP2023507926A
(en)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
Dosage regimens with esketamine to treat neuropsychiatric or neurological conditions
|
|
JP2023511370A
(en)
|
2020-01-22 |
2023-03-17 |
シーロス セラピューティクス， インコーポレイテッド |
Reduction of side effects of NMDA antagonists
|
|
AU2021242363A1
(en)
|
2020-03-27 |
2022-11-03 |
Homeostasis Therapeutics, Limited |
Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
|
|
JP7821116B2
(en)
|
2020-04-07 |
2026-02-26 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
Compositions and methods for preventing stress-induced fear, depression-like and anxiety-like behaviors
|
|
US12128012B2
(en)
|
2020-05-15 |
2024-10-29 |
University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
|
WO2021252971A2
(en)
|
2020-06-12 |
2021-12-16 |
Bexson Biomedical, Inc. |
Systems and devices for controlled drug delivery
|
|
US20230265046A1
(en)
|
2020-06-17 |
2023-08-24 |
Spirify Pharma Inc. |
Hydroxynorketamine analogues, compositions comprising same and methods of use thereof
|
|
IL312041A
(en)
|
2021-10-12 |
2024-06-01 |
Perception Neuroscience Inc |
R-ketamine salts and methods of use thereof
|
|
EP4493155A1
(en)
|
2022-03-14 |
2025-01-22 |
Perception Neuroscience, Inc. |
Pharmaceutical formulations of r-ketamine
|
|
US20250281426A1
(en)
|
2022-04-26 |
2025-09-11 |
Yichang Humanwell Pharmaceutical Co., Ltd. |
R-ketamine liquid preparation and use thereof
|
|
EP4642445A2
(en)
|
2022-12-28 |
2025-11-05 |
Perception Neuroscience, Inc. |
Methods of administering r-ketamine
|